ArticlePloS one2026
Unexpected diversification of DENV2 genotype III in Colombia: New Insights and application of the globalized nomenclature.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue is the most prevalent mosquito-borne viral disease worldwide and constitutes a major public health concern in Colombia. The disease is caused by four antigenically distinct dengue virus serotypes (DENV-1 to DENV-4), which share more than 65% genome identity. Although all four serotypes co-circulate in Colombia, secondary infections with DENV-2 have frequently been associated with more severe clinical outcomes. DENV-2 comprises six genotypes, of which genotype III has been the dominant lineage in the Americas over the past two decades. In this study, we investigated the evolutionary dynamics of DENV-2 genotype III in Colombia by analyzing available whole-genome coding sequences together with twenty-six newly generated genomes. Bayesian and maximum-likelihood phylogenetic approaches were applied to infer evolutionary relationships and temporal patterns. To harmonize lineage definitions and facilitate regional comparisons, we adopted the recently proposed hierarchical lineage nomenclature and used the Genome Detective Dengue typing tool for automated classification and consolidation of sequences from Colombia, Ecuador, and Venezuela. Phylogenetic analyses revealed a broadly distributed major lineage (previously designated D) circulating across the three countries, together with ongoing diversification and repeated introductions of genotype III within Colombia. Four minor lineages were identified, designated D.2.1, D.2.2, D.3.1, and D.3.2. Notably, the diversification of these minor lineages was accompanied by multiple non-synonymous substitutions. In particular, the two lineages currently circulating in Colombia, D.2.1 and D.2.2, are distinguished by approximately 20 mutations; however, the functional implications of these substitutions for viral virulence, pathogenicity, or vector competence remain unknown. These findings support the need for sustained and targeted genomic surveillance to detect and monitor emerging dengue virus lineages, prioritize them for epidemiological follow-up, and inform geographically focused public-health strategies. Overall, this study highlights the value of a globalized nomenclature, which enables the integration of genomic data across countries, facilitates the identification of emerging lineages in the region, and supports molecular surveillance efforts aimed at assessing their potential impact on disease presentation and public health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.